TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive In Brief: Trials Find DiBella Treatment Ineffective; Wistar Wins $1 Million Grant For Recruitment December 4, 1998